References
- Kumar SK, Callander NS, Alsina M, et al. NCCN guidelines insights: multiple myeloma, version 3.2018. J Natl Compr Canc Netw. 2018;16:11–20.
- Pratt G, Goodyear O, Moss P. Immunodeficiency and immunotherapy in multiple myeloma. Br J Haematol. 2007;138:563–579.
- Cooper NR. The classical complement pathway: activation and regulation of the first complement component. Adv Immunol. 1985;37:151–216.
- Bohlson SS, Fraser DA, Tenner AJ. Complement proteins C1q and MBL are pattern recognition molecules that signal immediate and long-term protective immune functions. Mol Immunol. 2007;44:33–43.
- Gaboriaud C, Thielens NM, Gregory LA, et al. Structure and activation of the C1 complex of complement: unraveling the puzzle. Trends Immunol. 2004;25:368–373.
- Hu SY, Jia XY, Yang XW, et al. Glomerular C1q deposition and serum anti-C1q antibodies in anti-glomerular basement membrane disease. BMC Immunol. 2013;14:42.
- Son M, Diamond B, Santiago-Schwarz F. Fundamental role of C1q in autoimmunity and inflammation. Immunol Res. 2015;63:101–106.
- Kohler PF, Muller-Eberhard HJ. Metabolism of human C1q. Studies in hypogammaglobulinemia, myeloma, and systemic lupus erythematosus. J Clin Invest. 1972;51:868–875.
- Bu X, Zheng Z, Wang C, et al. Significance of C4d deposition in the follicular lymphoma and MALT lymphoma and their relationship with follicular dendritic cells. Pathol Res Pract. 2007;203:163–167.
- Gasque P, Thomas A, Fontaine M, et al. Complement activation on human neuroblastoma cell lines in vitro: route of activation and expression of functional complement regulatory proteins. J Neuroimmunol. 1996;66:29–40.
- Lucas SD, Karlsson-Parra A, Nilsson B, et al. Tumor-specific deposition of immunoglobulin G and complement in papillary thyroid carcinoma. Hum Pathol. 1996;27:1329–1335.
- Niculescu F, Rus HG, Retegan M, et al. Persistent complement activation on tumor cells in breast cancer. Am J Pathol. 1992;140:1039–1043.
- Downs-Canner S, Magge D, Ravindranathan R, et al. Complement inhibition: a novel form of immunotherapy for colon cancer. Ann Surg Oncol. 2016;23:655–662.
- Tokumitsu S, Furuta Y, Kobayashi T, et al. Complete Clq deficiency associated with IgG multiple myeloma. Jpn J Med. 1989;28:216–218.
- Skoberne M, Somersan S, Almodovar W, et al. The apoptotic-cell receptor CR3, but not alphavbeta5, is a regulator of human dendritic-cell immunostimulatory function. Blood. 2006;108:947–955.
- Tripodo C, Porcasi R, Guarnotta C, et al. C1q production by bone marrow stromal cells. Scand J Immunol. 2007;65:308–309.